NO20072664L - Rapamycin analogues and their applications for the treatment of neurological, proliferative and inflammatory disorders - Google Patents
Rapamycin analogues and their applications for the treatment of neurological, proliferative and inflammatory disordersInfo
- Publication number
- NO20072664L NO20072664L NO20072664A NO20072664A NO20072664L NO 20072664 L NO20072664 L NO 20072664L NO 20072664 A NO20072664 A NO 20072664A NO 20072664 A NO20072664 A NO 20072664A NO 20072664 L NO20072664 L NO 20072664L
- Authority
- NO
- Norway
- Prior art keywords
- proliferative
- neurological
- applications
- treatment
- inflammatory disorders
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 230000002062 proliferating effect Effects 0.000 title abstract 2
- 230000000926 neurological effect Effects 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 206010019196 Head injury Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000009956 adenocarcinoma Diseases 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000003018 neuroregenerative effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SAMMENDRAG Foreliggende oppfinnelse tilveiebringer forbindelser med følgende struktur, hvor R1, R2, R4, R4', R6, R7 og R15 er definert ovenfor: . Disse forbindelsene er anvendelige for behandling av nevrologiske lidelser eller komplikasjoner på grunn av slag eller hodeskade; godartet eller ondartet neoplastisk sykdom, karsinomer og adenokarsinomer; proliferative lidelser; og inflammatoriske lidelser. Forbindelsene er derfor anvendelige som nevrobeskyttende og neuroregenerative, anti-proliferative og anti-inflammatoriske midler.SUMMARY The present invention provides compounds having the following structure, wherein R1, R2, R4, R4 ', R6, R7 and R15 are defined above:. These compounds are useful for treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders. Therefore, the compounds are useful as neuroprotective and neuroregenerative, anti-proliferative and anti-inflammatory agents.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63766604P | 2004-12-20 | 2004-12-20 | |
| PCT/US2005/045551 WO2006068932A2 (en) | 2004-12-20 | 2005-12-15 | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072664L true NO20072664L (en) | 2007-06-25 |
Family
ID=36087657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072664A NO20072664L (en) | 2004-12-20 | 2007-05-25 | Rapamycin analogues and their applications for the treatment of neurological, proliferative and inflammatory disorders |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US7276498B2 (en) |
| EP (1) | EP1828202B1 (en) |
| JP (1) | JP5094406B2 (en) |
| KR (1) | KR20070090913A (en) |
| CN (1) | CN101084227B (en) |
| AR (1) | AR052269A1 (en) |
| AT (1) | ATE549342T1 (en) |
| AU (1) | AU2005319454B2 (en) |
| BR (1) | BRPI0519495A2 (en) |
| CA (1) | CA2590155A1 (en) |
| CR (1) | CR9148A (en) |
| DK (1) | DK1828202T3 (en) |
| ES (1) | ES2380779T3 (en) |
| GT (1) | GT200500368A (en) |
| HN (1) | HN2005035605A (en) |
| IL (1) | IL183664A (en) |
| MX (1) | MX2007007408A (en) |
| NI (1) | NI200700157A (en) |
| NO (1) | NO20072664L (en) |
| NZ (1) | NZ574663A (en) |
| PE (1) | PE20060765A1 (en) |
| RU (1) | RU2394036C2 (en) |
| SG (1) | SG158143A1 (en) |
| TW (1) | TW200628152A (en) |
| UA (1) | UA94034C2 (en) |
| WO (1) | WO2006068932A2 (en) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ537829A (en) | 2002-07-30 | 2006-09-29 | Wyeth Corp | Parenteral formulations containing a rapamycin hydroxyester |
| AU2005219822A1 (en) * | 2004-03-02 | 2005-09-15 | Wyeth | Macrolides and methods for producing same |
| US7507752B2 (en) * | 2004-06-03 | 2009-03-24 | Wyeth | Biosynthetic gene cluster for the production of a complex polyketide |
| KR20070090931A (en) * | 2004-12-20 | 2007-09-06 | 와이어쓰 | Rapamycin derivatives and their use in the treatment of neurological disorders |
| SG158143A1 (en) * | 2004-12-20 | 2010-01-29 | Wyeth Corp | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| BRPI0619578A2 (en) * | 2005-12-07 | 2011-10-04 | Wyeth Corp | process for preparing a rapamycin 42-ester compound, method for isolating crude rapamycin 42-ester boronate from the mother liquor, method for purifying a rapamycin 42-ester boronate, and cci-779 boronate |
| AU2006322029A1 (en) * | 2005-12-07 | 2007-06-14 | Wyeth | Process for the preparation of purified crystalline CCI-779 |
| AR058283A1 (en) * | 2005-12-07 | 2008-01-30 | Wyeth Corp | METHODS FOR THE PREPARATION OF CRYSTALLINE RAPAMYCIN AND FOR THE MEASUREMENT OF CRYSTALINITY OF RAPAMYCIN COMPOUNDS USING DIFFERENTIAL BARRIDO CALORIMETRY |
| RU2008132779A (en) | 2006-03-07 | 2010-04-20 | Вайет (Us) | ANALOGUES OF MERIDAMICIN FOR TREATMENT OF NEURODEGENERATIVE DISEASES |
| US20100081681A1 (en) * | 2006-08-16 | 2010-04-01 | Blagosklonny Mikhail V | Methods and compositions for preventing or treating age-related diseases |
| TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
| US8414526B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids |
| US20080276935A1 (en) | 2006-11-20 | 2008-11-13 | Lixiao Wang | Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs |
| US8414910B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8425459B2 (en) | 2006-11-20 | 2013-04-23 | Lutonix, Inc. | Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent |
| US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
| US9700704B2 (en) | 2006-11-20 | 2017-07-11 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| US9737640B2 (en) | 2006-11-20 | 2017-08-22 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8414525B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
| US8430055B2 (en) | 2008-08-29 | 2013-04-30 | Lutonix, Inc. | Methods and apparatuses for coating balloon catheters |
| US8998846B2 (en) | 2006-11-20 | 2015-04-07 | Lutonix, Inc. | Drug releasing coatings for balloon catheters |
| WO2008094147A1 (en) * | 2007-01-29 | 2008-08-07 | Wyeth | Immunophilin ligands and methods for modulating immunophilin and calcium channel activity |
| JP2008305262A (en) * | 2007-06-08 | 2008-12-18 | Konica Minolta Business Technologies Inc | Printer introduction method in server and thin client environment |
| US20090136465A1 (en) | 2007-09-28 | 2009-05-28 | Intrexon Corporation | Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof |
| US8653045B2 (en) | 2008-02-05 | 2014-02-18 | The Johns Hopkins University | Induction of thyroid iodide-handling gene expression in human cancers |
| US20090209527A1 (en) * | 2008-02-19 | 2009-08-20 | Wyeth | Methods for Using Rapamycin Analogues in the Treatment of Neurological Disorders |
| DK2365802T3 (en) | 2008-11-11 | 2017-11-13 | Univ Texas | RAPAMYCINE MICROCAPLES AND USE FOR CANCER TREATMENT |
| DE102008060549A1 (en) | 2008-12-04 | 2010-06-10 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Drug-peptide construct for extracellular accumulation |
| CN102612564B (en) | 2009-04-10 | 2015-08-26 | 齐海燕 | New anti-aging agent and its identification method |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| WO2015161139A1 (en) | 2014-04-16 | 2015-10-22 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| CN107519499A (en) | 2010-03-23 | 2017-12-29 | 英特瑞克斯顿股份有限公司 | The carrier of condition expression treatment albumen, include the host cell of the carrier, and its application |
| ES2372077B2 (en) * | 2010-06-24 | 2012-05-18 | Universidad De Sevilla | USE OF RAPAMYCIN FOR THE TREATMENT OF COGNITIVE DEFICITS ASSOCIATED WITH THE DOWN SYNDROME. |
| EP2446886A1 (en) * | 2010-10-29 | 2012-05-02 | Fondazione Telethon | Autophagy regulators and the uses thereof in the treatment of collagen VI defective Muscular Dystrophies |
| CA2828411A1 (en) | 2011-03-04 | 2012-09-13 | Intrexon Corporation | Vectors conditionally expressing protein |
| EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
| US20150290176A1 (en) | 2012-10-12 | 2015-10-15 | The Board Of Regents Of The University Of Texas System | Use of mtor inhibitors to treat vascular cognitive impairment |
| ITMI20122065A1 (en) | 2012-12-03 | 2014-06-04 | Univ Padova | USE OF CFTR CORRECTORS IN THE TREATMENT OF STRUCTURAL MUSCLE PATHOLOGIES |
| EP2968281B1 (en) | 2013-03-13 | 2020-08-05 | The Board of Regents of The University of Texas System | Mtor inhibitors for prevention of intestinal polyp growth |
| AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| GB2538747B (en) * | 2015-05-27 | 2022-04-13 | Airbus Operations Ltd | A measuring apparatus for measuring properties of a surface |
| AU2016278040B2 (en) | 2015-06-16 | 2019-07-04 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| UY37343A (en) | 2016-07-25 | 2018-02-28 | Intrexon Corp | CONTROL OF THE PHENOTYPE IN PLANTS |
| MX2019005235A (en) | 2016-11-09 | 2019-12-05 | Intrexon Corp | Frataxin expression constructs. |
| ES2871499T3 (en) | 2017-05-15 | 2021-10-29 | Bard Inc C R | Medical device with drug elution coating and interlayer |
| WO2020076738A2 (en) * | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
| US11541152B2 (en) | 2018-11-14 | 2023-01-03 | Lutonix, Inc. | Medical device with drug-eluting coating on modified device surface |
| EP4272825A3 (en) * | 2019-01-22 | 2023-12-06 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
| JP7487228B2 (en) | 2019-04-08 | 2024-05-20 | バード・ペリフェラル・バスキュラー・インコーポレーテッド | Medical devices having a drug-eluting coating on a modified device surface |
| EP4185590A2 (en) * | 2020-07-21 | 2023-05-31 | Aeovian Pharmaceuticals, Inc. | Mtorc1 modulators and uses thereof |
| CN115887452A (en) * | 2022-01-27 | 2023-04-04 | 中以海德人工智能药物研发股份有限公司 | Application of rapamycin in treatment or prevention of hepatitis B |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (en) * | 1963-11-06 | 1968-12-19 | Bayer Ag | Process for the preparation of 2-position substituted benzoxazinones |
| DE1545824A1 (en) | 1965-06-21 | 1969-12-11 | Bayer Ag | Process for the preparation of 2-sulfonamido- or 2-sulfonhydrazido-benzoxazinones |
| GB1325047A (en) * | 1969-08-11 | 1973-08-01 | Ciba Geigy Ag | Rifamycin compounds and processes for their manufacture |
| US3686238A (en) * | 1970-01-19 | 1972-08-22 | Syntex Corp | Glycerol esterified with 2-naphthyl-acetic acids and fatty acids |
| US3900465A (en) * | 1973-04-05 | 1975-08-19 | Lepetit Spa | 3-formylrifamycin azines |
| US3905981A (en) * | 1973-10-12 | 1975-09-16 | Research Corp | N-dealkylation of tertiary amines |
| US4127720A (en) * | 1977-09-21 | 1978-11-28 | Bristol-Myers Company | Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity |
| JPH0262875A (en) | 1988-05-23 | 1990-03-02 | Wakunaga Pharmaceut Co Ltd | Novel isoindoline derivative |
| EP0533930A1 (en) | 1990-06-11 | 1993-03-31 | Fujisawa Pharmaceutical Co., Ltd. | Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease |
| DE4021404A1 (en) | 1990-07-05 | 1992-01-09 | Sandoz Ag | TRYCYCLIC COMPOUNDS HETEROATOMES, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
| GB2249027A (en) | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
| WO1992013862A1 (en) | 1991-02-05 | 1992-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Lactone compounds |
| US5604294A (en) * | 1991-09-05 | 1997-02-18 | Luly; Jay R. | Macrocyclic immunomodulators |
| ES2179823T3 (en) | 1991-09-05 | 2003-02-01 | Abbott Lab | MACROLIDO IMMUNOSUPRESOR. |
| ZA935111B (en) | 1992-07-17 | 1994-02-04 | Smithkline Beecham Corp | Rapamycin derivatives |
| ZA935112B (en) | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
| DE69430060T2 (en) | 1993-04-23 | 2002-11-07 | Abbott Laboratories, Abbott Park | RAPAMYCINE ANTIBODIES WITH OPEN RING |
| US7279561B1 (en) * | 1993-04-23 | 2007-10-09 | Wyeth | Anti-rapamycin monoclonal antibodies |
| US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| US5525610A (en) * | 1994-03-31 | 1996-06-11 | American Home Products Corporation | 42-Epi-rapamycin and pharmaceutical compositions thereof |
| US5696135A (en) * | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| ES2187660T3 (en) * | 1995-06-09 | 2003-06-16 | Novartis Ag | RAPAMYCIN DERIVATIVES |
| TW427904B (en) * | 1995-12-07 | 2001-04-01 | American Home Prod | Neuroprotective agents |
| US5717092A (en) * | 1996-03-29 | 1998-02-10 | Vertex Pharmaceuticals Inc. | Compounds with improved multi-drug resistance activity |
| US5780484A (en) * | 1996-11-13 | 1998-07-14 | Vertex Pharmaceuticals Incorporated | Methods for stimulating neurite growth with piperidine compounds |
| US6187784B1 (en) * | 1998-06-03 | 2001-02-13 | Gpi Nil Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
| EP1083872A1 (en) | 1998-06-03 | 2001-03-21 | GPI NIL Holdings, Inc. | Pipecolic acid derivative hair growth compositions and uses |
| US6376517B1 (en) | 1998-08-14 | 2002-04-23 | Gpi Nil Holdings, Inc. | Pipecolic acid derivatives for vision and memory disorders |
| US6015809A (en) * | 1998-08-17 | 2000-01-18 | American Home Products Corporation | Photocyclized rapamycin |
| DE69901907T2 (en) | 1998-08-17 | 2002-12-19 | Wyeth, Madison | PHOTOCYCLIZED RAPAMYCINE |
| AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| AU7124000A (en) | 1999-09-09 | 2001-04-10 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6569867B2 (en) * | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
| ES2283344T3 (en) | 1999-10-29 | 2007-11-01 | Kosan Biosciences, Inc. | RAPAMYCIN ANALOGS. |
| EP1282626A2 (en) | 2000-05-17 | 2003-02-12 | Kosan Biosciences, Inc. | Polyketide derivatives |
| BR0211905A (en) | 2001-08-22 | 2004-09-21 | Wyeth Corp | Rapamycin dialdehydes |
| DK1419154T3 (en) | 2001-08-22 | 2006-01-09 | Wyeth Corp | Rapamycin 29-enols |
| CA2492153C (en) | 2002-07-16 | 2012-05-08 | Biotica Technology Limited | Production of polyketide fkbp-ligand analogues |
| DE102004049700B4 (en) | 2004-10-12 | 2007-10-18 | Aircabin Gmbh | Power assist device with load-dependent power assistance |
| KR20070090931A (en) * | 2004-12-20 | 2007-09-06 | 와이어쓰 | Rapamycin derivatives and their use in the treatment of neurological disorders |
| SG158143A1 (en) | 2004-12-20 | 2010-01-29 | Wyeth Corp | Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative, and inflammatory disorders |
| RU2008132779A (en) | 2006-03-07 | 2010-04-20 | Вайет (Us) | ANALOGUES OF MERIDAMICIN FOR TREATMENT OF NEURODEGENERATIVE DISEASES |
-
2005
- 2005-12-15 SG SG200908383-3A patent/SG158143A1/en unknown
- 2005-12-15 JP JP2007546925A patent/JP5094406B2/en not_active Expired - Fee Related
- 2005-12-15 KR KR1020077013082A patent/KR20070090913A/en not_active Ceased
- 2005-12-15 PE PE2005001466A patent/PE20060765A1/en not_active Application Discontinuation
- 2005-12-15 AU AU2005319454A patent/AU2005319454B2/en not_active Expired - Fee Related
- 2005-12-15 BR BRPI0519495-4A patent/BRPI0519495A2/en not_active IP Right Cessation
- 2005-12-15 CN CN2005800437154A patent/CN101084227B/en not_active Expired - Fee Related
- 2005-12-15 TW TW094144448A patent/TW200628152A/en unknown
- 2005-12-15 HN HN2005035605A patent/HN2005035605A/en unknown
- 2005-12-15 GT GT200500368A patent/GT200500368A/en unknown
- 2005-12-15 UA UAA200706849A patent/UA94034C2/en unknown
- 2005-12-15 EP EP05849447A patent/EP1828202B1/en not_active Not-in-force
- 2005-12-15 AT AT05849447T patent/ATE549342T1/en active
- 2005-12-15 DK DK05849447.7T patent/DK1828202T3/en active
- 2005-12-15 ES ES05849447T patent/ES2380779T3/en active Active
- 2005-12-15 RU RU2007119584/04A patent/RU2394036C2/en not_active IP Right Cessation
- 2005-12-15 MX MX2007007408A patent/MX2007007408A/en active IP Right Grant
- 2005-12-15 AR ARP050105290A patent/AR052269A1/en not_active Application Discontinuation
- 2005-12-15 NZ NZ574663A patent/NZ574663A/en not_active IP Right Cessation
- 2005-12-15 US US11/300,839 patent/US7276498B2/en not_active Expired - Fee Related
- 2005-12-15 WO PCT/US2005/045551 patent/WO2006068932A2/en not_active Ceased
- 2005-12-15 CA CA002590155A patent/CA2590155A1/en not_active Abandoned
-
2007
- 2007-01-26 US US11/698,504 patent/US7560457B2/en not_active Expired - Fee Related
- 2007-05-24 CR CR9148A patent/CR9148A/en not_active Application Discontinuation
- 2007-05-25 NO NO20072664A patent/NO20072664L/en not_active Application Discontinuation
- 2007-06-04 IL IL183664A patent/IL183664A/en not_active IP Right Cessation
- 2007-06-18 NI NI200700157A patent/NI200700157A/en unknown
- 2007-08-14 US US11/893,090 patent/US7470682B2/en not_active Expired - Fee Related
-
2008
- 2008-11-24 US US12/276,668 patent/US20090203682A1/en not_active Abandoned
-
2009
- 2009-06-09 US US12/481,211 patent/US7795252B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20072664L (en) | Rapamycin analogues and their applications for the treatment of neurological, proliferative and inflammatory disorders | |
| NO20072665L (en) | Rapamycin derivatives and their use in the treatment of neurological disorders | |
| CY2013022I1 (en) | COMPOSITIONS FOR THE THERAPEUTIC TREATMENT OF GASTROINTESTINAL DISORDERS | |
| EA200900663A1 (en) | TREATMENT OF "DRY EYE" SYNDROME | |
| NO20070247L (en) | Amino-5,5-diphenylimidazolone derivatives for inhibition of beta-secretase | |
| DK1955700T3 (en) | Therapeutic treatment of androgen receptor-related disorders | |
| AR028824A1 (en) | NPY-5 ANTAGONIST COMPOUNDS AND ITS USE IN THE MANUFACTURE OF MEDICINES. | |
| ECSP034809A (en) | CICLOBUTENO-1,2-DIONAS 3,4-DISUSTITUTED AS LIGANDS OF THE CXC CHEMOCINE RECEIVER | |
| PA8571001A1 (en) | 2- (2,6-DICLOROPHENYL) -DIARYLIMIDAZOLS | |
| ATE361288T1 (en) | N-(3,-DIMETHYLINDOLINE-6-YL)Ä2-Ä(4- | |
| ATE384058T1 (en) | THIAZOLE DERIVATIVES | |
| ATE427759T1 (en) | TREATMENT OF OBESITY AND RELATED DISEASES | |
| BR0316723A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| BR0215151A (en) | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | |
| EP1251126A3 (en) | Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation | |
| PL1891029T3 (en) | Organic compounds for the treatment of imflammatory or alleric conditions | |
| BRPI0508051A (en) | heteroarylaminopyrazole derivatives usable for the treatment of diabetes | |
| ECSP045156A (en) | INDOLILALQUILAMINE DERIVATIVES AS LIGANDOS 5-HIDROXITRIPTAMINA-6 | |
| DE60014136D1 (en) | SAPOGENINE DERIVATIVES FOR TREATING COGNITIVE DISORDERS | |
| EA200600071A1 (en) | Derivatives of N-phenylpyrazine and Methods for the Prevention or Treatment of Diseases Associated with 5HT-Receptor | |
| PT1562954E (en) | CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DEMANDING DISEASE I.A. | |
| CL2008003027A1 (en) | Compounds derived from 5,6-diaryl pyridines substituted at positions 2 and 3; intermediate compounds and their use; pharmaceutical composition; and use to treat and / or prevent psychiatric, metabolic, inflammatory disorders, for the prevention of pain, among other diseases. | |
| CR8696A (en) | BETA-USEFUL CARBOLINS TO TREAT INFLAMMATORY DISEASES | |
| DK1463735T3 (en) | Imidazo-2,1-B -1,3,4-thiadiazole sulfonamides | |
| EA200870093A1 (en) | APPLICATION OF DERIVATIVES OF BENZEN-CONDENSED HETEROCYCLIC SULFAMIDE FOR TREATMENT OF OBESITY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |